| Identification | Back Directory | [Name]
(R)-N-(2-(1H-indol-3-yl)-1-(4-(4-methoxybenzyl)-5-phenethyl-4H-1,2,4-triazol-3-yl)ethyl)-2-aminoacetamide hydrochloride | [CAS]
925238-89-7 | [Synonyms]
JMV 2959
AEZS-123)
JMV 2959
(JMV2959
(R)-N-(2-(1H-indol-3-yl)-1-(4-(4-methoxybenzyl)-5-phenethyl-4H-1,2,4-triazol-3-yl)ethyl)-2-aminoacetamide hydrochloride
Acetamide, 2-amino-N-[(1R)-2-(1H-indol-3-yl)-1-[4-[(4-methoxyphenyl)methyl]-5-(2-phenylethyl)-4H-1,2,4-triazol-3-yl]ethyl]- | [Molecular Formula]
C30H32N6O2 | [MDL Number]
MFCD31619321 | [MOL File]
925238-89-7.mol | [Molecular Weight]
508.61 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:25.0(Max Conc. mg/mL);49.15(Max Conc. mM) | [form ]
Solid | [color ]
White to off-white | [InChIKey]
OZSZELOMMMKWTM-HHHXNRCGSA-N | [SMILES]
C(N[C@@H](C1N(CC2=CC=C(OC)C=C2)C(CCC2=CC=CC=C2)=NN=1)CC1C2=C(NC=1)C=CC=C2)(=O)CN |
| Hazard Information | Back Directory | [Uses]
JMV 2959 is a ghrelin antagonist affecting the hunger state and release of growth hormone. It indirectly may influence behaviours associated with addictive alcohol and drug disorders as well as schizophrenia. | [in vivo]
When administered alone, it does not increase food intake and does not significantly stimulate growth hormone (GH) release[1]. JMV 2959 dose dependently decreases the startle response (F(3.42)=4.4, p<0.01) and increases %prepulse inhibition (PPI) (F(3.42)=3.9, p<0.05) in the prepulse inhibition paradigm. The alteration in the startle response is mainly due to a 27% decrease in the startle seen in the highest dose of JMV 2959 (6 mg/kg) compare to vehicle (p<0.05)[2]. 6 mg/kg JMV 2959 induces a significant suppression of locomotion on days 1 to 7 relative to baseline day 0 (F(7,49)=2.21, p<0.05). Results also reveal a significant interaction between JMV 2959 treatment and day (F(1,14)=4.397, p<0.05)[3]. | [storage]
Store at -20°C |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|